Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/2 trial of Coversin in the inflammatory-mediated eye disorder Atopic Keratoconjunctivitis (AKC)

Trial Profile

A phase 1/2 trial of Coversin in the inflammatory-mediated eye disorder Atopic Keratoconjunctivitis (AKC)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Sep 2018

At a glance

  • Drugs Nomacopan (Primary)
  • Indications Keratoconjunctivitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Sep 2018 Status changed from planning to recruiting, according to an Akari Therapeutics media release.
    • 17 Aug 2018 According to an Akari Therapeutics media release, this study is expected to start in Q3 2018, with data anticipated Q1 2019.
    • 09 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top